Immunome INC DEF 14A proxy statements

Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.

NASDAQ
Immunome, Inc. has filed a definitive proxy statement pursuant to Section 14(a) of the Securities Exchange Act of 1934.
NASDAQ
Immunome, Inc. announces its 2025 Annual Meeting of Stockholders to be held virtually on June 10, 2025, to elect directors and ratify the appointment of Ernst & Young LLP as the independent accounting firm.
NASDAQ
Immunome, Inc. announces its 2024 Annual Meeting of Stockholders to be held virtually on June 12, 2024, with key proposals including the election of directors and ratification of the company's independent auditor.
NASDAQ
Immunome, Inc. has scheduled its 2024 Annual Meeting of Stockholders to be held virtually on June 12, 2024, to elect directors and ratify the appointment of Ernst & Young LLP as the company's independent accounting firm.